The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer
Open accessAbstract
CONTEXT: Despite a lack of data, increasing numbers of patients are receiving primary androgen deprivation therapy (PADT) as an alternative to surgery, radiation, or conservative management for the treatment of localized prostate cancer. OBJECTIVE: To evaluate the association between PADT and survival in elderly men with localized prostate cancer. DESIGN, SETTING, AND PATIENTS: A population-based cohort study of 19,271 men aged 66 years or older receiving Medicare who did not receive definitive local therapy for clinical stage T1-T2 prostate cancer. These patients were diagnosed in 1992-2002 within predefined US geographical areas, with follow-up through December 31, 2006, for all-cause mortality and through December 31, 2004, for prostate cancer-specific mortality. Instrumental variable analysis was used to address potential biases associated with unmeasured confounding variables. MAIN OUTCOME MEASURES: Prostate cancer-specific survival and overall survival. RESULTS: Among patients with localized prostate cancer (median age, 77 years), 7867 (41%) received PADT, and 11,404 were treated with conservative management, not including PADT. During the follow-up period, there were 1560 prostate cancer deaths and 11,045 deaths from all causes. Primary androgen deprivation therapy was associated with lower 10-year prostate cancer-specific survival (80.1% vs 82.6%; hazard ratio [HR], 1.17; 95% confidence interval [CI], 1.03-1.33) and no increase in 10-year overall survival (30.2% vs 30.3%; HR, 1.00; 95% CI, 0.96-1.05) compared with conservative management. However, in a prespecified subset analysis, PADT use in men with poorly differentiated cancer was associated with improved prostate cancer-specific survival (59.8% vs 54.3%; HR, 0.84; 95% CI, 0.70-1.00; P = .049) but not overall survival (17.3% vs 15.3%; HR, 0.92; 95% CI, 0.84-1.01). CONCLUSION: Primary androgen deprivation therapy is not associated with improved survival among the majority of elderly men with localized prostate cancer when compared with conservative management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Identification of Causal Effects Using Instrumental Variables
Angrist, J. D., Imbens, G. W., & Rubin, D. B. (1996) · Journal of the American Statistical Association · doi:10.1080/01621459.1996.10476902 · Cited by 4,230
Development of a comorbidity index using physician claims data
Klabunde, C. N., Potosky, A. L., Legler, J. M., & Warren, J. L. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00256-0 · Cited by 1,845
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · PubMed · doi:10.1097/01.mlr.0000020942.47004.03 · Cited by 1,714
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Stukel, T. A., Fisher, E. S., Wennberg, D. E., Alter, D. A., Gottlieb, D. J., & Vermeulen, M. J. (2007) · JAMA · doi:10.1001/jama.297.3.278 · Cited by 786
D'Amico, A. V., Manola, J., Loffredo, M., Renshaw, A. A., DellaCroce, A., & Kantoff, P. W. (2004) · JAMA · doi:10.1001/jama.292.7.821 · Cited by 767
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697
Potosky, A. L., Davis, W. W., Hoffman, R. M., Stanford, J. L., Stephenson, R. A., Penson, D. F., & Harlan, L. C. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh259 · Cited by 680
(1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.d01-6840.x · Cited by 654
Adib, R., Anderson, J., Ashken, M. H., Baumber, C. D., CRA, B. D., BEYNON, L. L., Blaxland, J. W., Boag, V., Bolger, J., Boreham, J., et al. (1997) · Kent Academic Repository (University of Kent) · Cited by 551
Risk Adjustment in Outcome Assessment: the Charlson Comorbidity Index
Sicotte, C., Tilquin, C., & D’Hoore, W. (1993) · Methods of Information in Medicine · doi:10.1055/s-0038-1634956 · Cited by 545
D'Amico, A. V., Denham, J. W., Crook, J., Chen, M.-H., Goldhaber, S. Z., Lamb, D. S., Joseph, D., Tai, K.-H., Malone, S., Ludgate, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3369 · Cited by 501
Long-term Survival Among Men With Conservatively Treated Localized Prostate Cancer
Albertsen, P. C. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530080042039 · Cited by 464
Isaacs, J. T., & Coffey, D. S. (1981) · PubMed · Cited by 371
COOPERBERG, M. R., BROERING, J. M., LITWIN, M. S., LUBECK, D. P., MEHTA, S. S., HENNING, J. M., CARROLL, P. R., & the CaPSURE INVESTIGATORS (2004) · Journal of Urology · doi:10.1097/01.ju.0000107247.81471.06 · Cited by 340
National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer
Cooperberg, M. R., Grossfeld, G. D., Lubeck, D. P., & Carroll, P. R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.981 · Cited by 329
Studer, U. E., Whelan, P., Albrecht, W., Casselman, J., de Reijke, T., Hauri, D., Loidl, W., Isorna, S., Sundaram, S. K., Debois, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7423 · Cited by 327
Shahinian, V. B., Kuo, Y., Freeman, J. L., Orihuela, E., & Goodwin, J. S. (2005) · Cancer · doi:10.1002/cncr.20955 · Cited by 323
Androgens, insulin resistance and vascular disease in men
Kapoor, D., Malkin, C. J., Channer, K. S., & Jones, T. H. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02299.x · Cited by 317
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
MCLEOD, D. G., IVERSEN, P., SEE, W. A., MORRIS, T., ARMSTRONG, J., WIRTH, M. P., & the Casodex Early Prostate Cancer Trialists’ Group (2006) · BJU International · doi:10.1111/j.1464-410x.2005.06051.x · Cited by 277
Earle, C. C., Tsai, J. S., Gelber, R. D., Weinstein, M. C., Neumann, P. J., & Weeks, J. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1064 · Cited by 248
HYPOGONADISM AND METABOLIC SYNDROME: IMPLICATIONS FOR TESTOSTERONE THERAPY
MAKHSIDA, N., SHAH, J., YAN, G., FISCH, H., & SHABSIGH, R. (2005) · Journal of Urology · doi:10.1097/01.ju.0000169490.78443.59 · Cited by 229
Potosky, A. L. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.6.430 · Cited by 195
Mutation of the androgen receptor causes oncogenic transformation of the prostate.
Han, G., Buchanan, G., Ittmann, M., Harris, J. M., Yu, X., DeMayo, F. J., Tilley, W., & Greenberg, N. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408925102 · Cited by 192
Impact of Referral Patterns on the Use of Chemotherapy for Lung Cancer
Earle, C. C., Neumann, P. J., Gelber, R. D., Weinstein, M. C., & Weeks, J. C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.142 · Cited by 176
Studer, U. E., Collette, L., Whelan, P., Albrecht, W., Casselman, J., de Reijke, T. M., Knönagel, H., Loidl, W. C., Isorna, S., Sundaram, S. K., et al. (2007) · European Urology · doi:10.1016/j.eururo.2007.12.032 · Cited by 151
Determining Cause of Death in Prostate Cancer: Are Death Certificates Valid?
Penson, D. F., Albertsen, P. C., Nelson, P. S., Barry, M., & Stanford, J. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.23.1822 · Cited by 129
Determinants of Androgen Deprivation Therapy Use for Prostate Cancer: Role of the Urologist
Shahinian, V. B., Kuo, Y., Freeman, J. L., & Goodwin, J. S. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj230 · Cited by 129
Kawakami, J., Cowan, J. E., Elkin, E. P., Latini, D. M., DuChane, J., & Carroll, P. R. (2006) · Cancer · doi:10.1002/cncr.21799 · Cited by 107
Albertsen, P. C., WALTERS, S., & Hanley, J. A. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67915-3 · Cited by 104
Fowler, J. E., Terrell, F. L., & Renfroe, L. D. (1996) · The Journal of Urology · doi:10.1016/s0022-5347(01)65489-2 · Cited by 102
Schröder, F. H., Kurth, K., Fosså, S. D., Hoekstra, W. J., Karthaus, P., Debois, M., & Collette, L. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000135742.13171.d2 · Cited by 100
Iversen, P., Johansson, J., Lodding, P., Lukkarinen, O. A., Lundmo, P. I., Klarskov, P., Tammela, T. L. J., Taşdemir, İ., Morris, T., Carroll, K., et al. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000139719.99825.54 · Cited by 98
Studer, U. E., HAURI, D., Hanselmann, S., Chollet, D., Leisinger, H., Gasser, T., Senn, E., Trinkler, F. B., Tscholl, R., Thalmann, G. N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.514 · Cited by 94
Labrie, F., Candas, B., Gomez, J., & Cusan, L. (2002) · Urology · doi:10.1016/s0090-4295(02)01639-4 · Cited by 89
Banach-Petrosky, W. A., Jessen, W. J., Ouyang, X., Gao, H., Rao, J., Quinn, J., Aronow, B. J., & Abate-Shen, C. T. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2887 · Cited by 81
Weight, C., Klein, E. A., & Jones, J. S. (2008) · Cancer · doi:10.1002/cncr.23421 · Cited by 80
Akaza, H., Homma, Y., Usami, M., Hirao, Y., Tsushima, T., Okada, K., Yokoyama, M., Ohashi, Y., Aso, Y., & THE PROSTATE CANCER STUDY GROUP (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06349.x · Cited by 71
D'Amico, A. V., Loffredo, M. J., Renshaw, A. A., Loffredo, B., & Chen, M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8239 · Cited by 36
Akaza, H. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00180.x · Cited by 34
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Mohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Harris, W. P., Mostaghel, E. A., Nelson, P. S., & Montgomery, B. (2009) · Nature Clinical Practice Urology · doi:10.1038/ncpuro1296 · Cited by 877
Metadata
- Authors
- Lu-Yao, G. L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2008-07-09
- Volume
- 300
- Issue
- 2
- Pages
- 173
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2065616395
- Cited by
- 315
- References
- 48
- FWCI
- 36.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.